1. Home
  2. ATYR vs PCYO Comparison

ATYR vs PCYO Comparison

Compare ATYR & PCYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • PCYO
  • Stock Information
  • Founded
  • ATYR 2005
  • PCYO 1976
  • Country
  • ATYR United States
  • PCYO United States
  • Employees
  • ATYR N/A
  • PCYO N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • PCYO Water Supply
  • Sector
  • ATYR Health Care
  • PCYO Utilities
  • Exchange
  • ATYR Nasdaq
  • PCYO Nasdaq
  • Market Cap
  • ATYR 330.7M
  • PCYO 271.7M
  • IPO Year
  • ATYR 2015
  • PCYO N/A
  • Fundamental
  • Price
  • ATYR $4.32
  • PCYO $11.49
  • Analyst Decision
  • ATYR Strong Buy
  • PCYO
  • Analyst Count
  • ATYR 6
  • PCYO 0
  • Target Price
  • ATYR $18.60
  • PCYO N/A
  • AVG Volume (30 Days)
  • ATYR 1.0M
  • PCYO 35.5K
  • Earning Date
  • ATYR 03-13-2025
  • PCYO 04-09-2025
  • Dividend Yield
  • ATYR N/A
  • PCYO N/A
  • EPS Growth
  • ATYR N/A
  • PCYO 103.72
  • EPS
  • ATYR N/A
  • PCYO 0.55
  • Revenue
  • ATYR $235,000.00
  • PCYO $29,113,000.00
  • Revenue This Year
  • ATYR N/A
  • PCYO N/A
  • Revenue Next Year
  • ATYR $1,299.74
  • PCYO N/A
  • P/E Ratio
  • ATYR N/A
  • PCYO $20.89
  • Revenue Growth
  • ATYR N/A
  • PCYO 56.25
  • 52 Week Low
  • ATYR $1.42
  • PCYO $8.94
  • 52 Week High
  • ATYR $4.66
  • PCYO $14.63
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 63.39
  • PCYO 43.48
  • Support Level
  • ATYR $3.38
  • PCYO $11.23
  • Resistance Level
  • ATYR $3.81
  • PCYO $12.25
  • Average True Range (ATR)
  • ATYR 0.27
  • PCYO 0.28
  • MACD
  • ATYR 0.06
  • PCYO 0.03
  • Stochastic Oscillator
  • ATYR 74.44
  • PCYO 25.49

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. It designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The company's services include water production, storage, treatment, bulk transmission to retail distribution systems, wastewater collection and treatment, irrigation water treatment and transmission, construction management, billing, and collection. The land resource development segment includes all the activities necessary to develop and sell finished lots.

Share on Social Networks: